BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 31

• Biotech Bay

  Apogee Therapeutics, Inc. Announces Pricing of Upsized $420 Million Underwritten Public Offering

  Apogee Therapeutics, Inc. announced the pricing of its upsized previously announced underwritten public offering of 6,774,193 shares of common stock at a public offering price per share of $62.00.

  March 7, 2024

   · 

  5 min read
• Business

  Extendicare Announces 2023 Fourth Quarter and Year End Results

  Extendicare Inc. reported results for the three and twelve months ended December 31, 2023.

  March 7, 2024

   · 

  18 min read
• VISEN Announces Acceptance of a Biologics License Application for Lonapegsomatropin in China

  VISEN Pharmaceuticals, an innovative biopharmaceutical company focused on endocrine diseases, announced that the Biologics License Application for Lonapegsomatropin was accepted by the China National Medical Products Administration.

  March 7, 2024

   · 

  2 min read
• Oxford BioTherapeutics Announces Launch of Enhanced Discovery Platform, OGAP®-Verify, at World ADC Conference 2024

  Oxford BioTherapeutics announces significant technological advances to its drug discovery platform OGAP® with a new version to be launched at the 14th Annual World ADC Conference in London named OGAP®-Verify.

  March 7, 2024

   · 

  6 min read
• Drug Development

  Immuron Announces Positive Results Support Travelan® progress to Phase 3 Clinical Trials in the US

  Immuron Limited is pleased to announce the interim topline results confirming that a single daily dose of Travelan® is effective in prevention of moderate to severe diarrhea following challenge with enterotoxigenic Escherichia coli.

  March 7, 2024

   · 

  7 min read
• BioMidwest

  Zomedica Announces Publication of Case Series Highlighting Success with PulseVet(R) Shock Wave Therapy for Difficult to Treat Fibrotic Myopathy in Working Dogs

  Zomedica Corp. announced the publication of a case series article supporting the use of PulseVet electro-hydraulic shock wave therapy to successfully treat canine patients with fibrotic myopathy.

  March 7, 2024

   · 

  7 min read
• Business

  BioNTech Announces Planned Retirement of Sean Marett

  BioNTech SE announced that Sean Marett, Chief Business and Commercial Officer, will retire as planned from the Management Board of BioNTech.

  March 7, 2024

   · 

  7 min read
• Business

  Stevanato Group Delivers Double-Digit Revenue Growth in Fiscal Year 2023

  Stevanato Group S.p.A. announced its financial results for the fourth quarter and full year 2023.

  March 7, 2024

   · 

  21 min read
• Business

  Protalix BioTherapeutics to Announce Fiscal Year 2023 Financial and Business Results on March 14, 2024

  Protalix BioTherapeutics, Inc. today announced that it will release its financial results for the fiscal year ended December 31, 2023 and provide a business update on Thursday, March 14, 2024.

  March 7, 2024

   · 

  2 min read
• Drug Development

  NodThera’s NLRP3 Inhibitor NT-0796 Reverses Neuroinflammation in Parkinson’s Disease Phase Ib/IIa Trial

  NodThera today announces positive data from its Phase Ib/IIa study in Parkinson’s disease patients, evaluating the effects of its oral, brain-penetrant NLRP3 inflammasome inhibitor NT-0796, on inflammatory and disease-specific biomarkers in the blood and cerebrospinal fluid (CSF).

  March 7, 2024

   · 

  5 min read